respiratory failure News
-
Lungpacer Medical, Inc. Presents Preclinical Results at the European Respiratory Society’s Respiratory Failure & Mechanical Ventilation Conference, February 2020, Berlin, Germany
The inaugural ERS Respiratory Failure and Mechanical Ventilation conference gathered more than 400 delegates from 60 countries, representing a diverse mix of world-leading respiratory scientists, clinicians and allied healthcare professionals. Delegates witnessed more than 40 scientific sessions and there were over 70 abstracts presented, featuring cutting-edge clinical and scientific ...
-
Third Pole Therapeutics to Present at Biotech Showcase 2020
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today its Chief Executive Officer Bill Athenson will present at Biotech Showcase 2020 to be held January 13-15, 2020 at the Hilton San Francisco Union Square. During the presentation Mr. Athenson will discuss Third Pole’s strategy for its ...
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
FDA Grants the Hemolung® De Novo Clearance
PITTSBURGH – (BUSINESS WIRE) – November 15, 2021 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the Company De Novo clearance for the Hemolung Respiratory Assist System. The Hemolung ...
-
200 Years of Patient Care. Patient Pioneer: The Story of Courtney Joyce
Last week the hospital marked a significant milestone – the 175th anniversary of the first public demonstration of ether in surgery, considered one of most game-changing events in medical history. In the spirit of that Oct. 16, 1846 landmark, the MGH, fittingly, shares the story of Courtney Joyce, who was the first patient at the hospital to benefit from inhaled nitric oxide (NO) as a ...
-
Third Pole Therapeutics Issued New U.S. Patents
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems as follows: US Patent No. 10,286.176 issued on May 14, 2019 titled ...
-
Patient Enrollment is Complete in the DOD-Funded Study of Extracorporeal Hemopurification of Critically Ill COVID-19 Patients
MARTINEZ, Calif. – PURIFY OBS, an observational study of critically-ill COVID patients treated with the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100), has recently completed enrollment. A multicenter effort led by the US Department of Defense (DOD) published interim results in April 2021. Observations included dramatic improvement in survival and reduction in median ICU ...
-
Treatment for critically ill COVID patients results in significant improvement in survival rate according to new study
Patient survival doubles when Seraph 100 is used earlier during ICU stay MARTINEZ, Calif. – Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released ...
-
Third Pole Therapeutics to Participate in H.C. Wainwright BioConnect and BIO Partnering at JPM during J.P. Morgan 40th Annual Healthcare Conference
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference. Details of the events and presentation are as ...
-
9/11 Environmental Health Services Offered at New Locations
NEW YORK, New York, September 20, 2007 (ENS) - The World Trade Center Environmental Health Center at Bellevue Hospital, a city-funded program that offers free, high quality health services to people experiencing health problems as a result of 9/11, is expanding to two additional locations. New York Mayor Michael Bloomberg and Health and Hospitals Corporation President Alan Aviles today said ...
-
OXITONE, the World`s First FDA-Cleared Wrist Sensor, Pulse Oximeter Monitoring Device to Detect the Early Symptoms of COVID-19 and Other Chronic Diseases
IRVINE, Calif., May 28, 2020 (Newswire.com) - betweenMD is very excited to announce our partnership with Oxitone, makers of the world's first FDA-cleared risk monitoring device. Oxitone developed a wearable monitoring device, specifically designed and FDA-cleared for in-home use for patients with respiratory failure. This unique solution is for prolonged monitoring for those at risk for ...
-
ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Seraph 100 used for Blood Purification and Pathogen Reduction in Sepsis and COVID-19 Treatments MARTINEZ, Calif. – ExThera Medical and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExThera’s Seraph® 100 Microbind® Affinity Blood Filter in Mexico. In 2021, ExThera ...
-
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk
Inflammatix a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads the immune system to predict severe respiratory failure risk in COVID-19 patients. The diagnostic is being developed to help physicians make better hospital admission ...
-
China’s COVID-19 wave forecast to have two peaks where cases could reach 4.2 million a day
China is predicted to see two peaks in cases as COVID-19 spreads throughout the country, the first peak in mid-January and the second in early March. New modelling by Airfinity has examined data from China’s regional provinces. The current outbreak is growing more rapidly in some regions than in others. Cases are currently rising much more quickly in Beijing and Guangdong. Using the ...
-
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company’s U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine. ...
-
FDA Grants ALung Emergency Use Authorization (EUA) to the ALung for the Treatment of COVID-19
PITTSBURGH – (BUSINESS WIRE) – April 24, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the Company Emergency Use Authorization (EUA) designation to the Hemolung® Respiratory ...
-
Third Pole Therapeutics Names Bill Athenson New CEO
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer, the company announced today. David Zapol, Third Pole’s founding CEO, will continue providing strategic counsel to Third Pole. Athenson joins Third Pole building on the ...
-
Medimprove – A New Private Clinic For Lung Revalidation With FRI
To address the need for better chronic respiratory care, Prof De Backer, emeritus Professor Pulmonology at the University of Antwerp and Chairman of The board of FLUIDDA NV, has opened a private clinic in Belgium near the Fluidda headquarters in Kontich, Belgium. The clinic uses a multidisciplinary approach for chronic respiratory failure. Care at this private clinic can involve exercise ...
By Fluidda
-
Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. New real-world data will be presented evaluating SOLIRIS® (eculizumab) for the treatment of generalized myasthenia gravis (gMG) in the United ...
-
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you